|
1
|
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
|
Lancet
|
2008
|
13.34
|
|
2
|
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
|
N Engl J Med
|
2004
|
9.13
|
|
3
|
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
|
N Engl J Med
|
2005
|
6.86
|
|
4
|
The Seattle Heart Failure Model: prediction of survival in heart failure.
|
Circulation
|
2006
|
6.58
|
|
5
|
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.
|
Eur Heart J
|
2007
|
2.56
|
|
6
|
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.
|
Eur Heart J
|
2012
|
2.29
|
|
7
|
The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients.
|
EuroIntervention
|
2013
|
1.72
|
|
8
|
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
J Am Coll Cardiol
|
2006
|
1.71
|
|
9
|
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.
|
J Am Coll Cardiol
|
2013
|
1.65
|
|
10
|
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.
|
J Am Coll Cardiol
|
2012
|
1.64
|
|
11
|
Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort.
|
J Am Coll Cardiol
|
2013
|
1.55
|
|
12
|
Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres.
|
Trials
|
2010
|
1.53
|
|
13
|
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
|
Eur J Heart Fail
|
2012
|
1.53
|
|
14
|
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
|
J Card Fail
|
2005
|
1.39
|
|
15
|
Targeting myocardial substrate metabolism in heart failure: potential for new therapies.
|
Eur J Heart Fail
|
2012
|
1.36
|
|
16
|
Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).
|
Eur J Heart Fail
|
2010
|
1.06
|
|
17
|
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
|
Heart Fail Rev
|
2012
|
1.05
|
|
18
|
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
|
Eur J Heart Fail
|
2005
|
1.04
|
|
19
|
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
|
J Card Fail
|
2013
|
1.02
|
|
20
|
ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association.
|
Europace
|
2012
|
1.01
|
|
21
|
Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.
|
Eur J Heart Fail
|
2010
|
1.01
|
|
22
|
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.
|
Eur J Heart Fail
|
2013
|
0.97
|
|
23
|
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
|
Eur J Heart Fail
|
2013
|
0.90
|
|
24
|
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
|
Am J Cardiol
|
2008
|
0.87
|
|
25
|
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
|
Eur J Heart Fail
|
2010
|
0.84
|
|
26
|
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2008
|
0.83
|
|
27
|
Where are we with the management of hypertension? From science to clinical practice.
|
J Clin Hypertens (Greenwich)
|
2009
|
0.81
|
|
28
|
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period.
|
Obesity (Silver Spring)
|
2009
|
0.80
|
|
29
|
Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function.
|
Am J Cardiol
|
2008
|
0.79
|
|
30
|
Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.
|
Clin Cardiol
|
2010
|
0.78
|
|
31
|
Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.
|
Clin Res Cardiol
|
2012
|
0.75
|
|
32
|
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF.
|
Eur J Heart Fail
|
2015
|
0.75
|
|
33
|
Atrial Fibrillation Ablation Pilot Study: a new feature of the EURObservational Research Programme.
|
Eur Heart J
|
2011
|
0.75
|
|
34
|
Heart Failure Pilot protocol.
|
Eur Heart J
|
2010
|
0.75
|
|
35
|
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction.
|
Am Heart J
|
2011
|
0.75
|
|
36
|
Transcatheter Valve Treatment Pilot Registry: design and current status.
|
Eur Heart J
|
2012
|
0.75
|
|
37
|
Use of valsartan in post-myocardial infarction and heart failure patients.
|
J Renin Angiotensin Aldosterone Syst
|
2006
|
0.75
|